Pohl, Roderike,Kashyap, Nandini,Steiner, Solomon S.
申请号：
AU2009204309
公开号：
AU2009204309B2
申请日:
2009.01.05
申请国别(地区):
AU
年份:
2012
代理人:
摘要：
Injectable insulin formulations that are capable of modifying the amount ofinsulin released based on the patient's tissue glucose levels, methodsfor making and using these formulations are described herein. The formulationmay be administered via subcutaneous, intradermal or intramuscular administration.In one preferred embodiment, the formulations are administered via subcutaneousinjection. The formulations contain insulin, an oxidizing agent or enzyme anda reducing agent or enzyme, a diluent and optionally one or more thickening agents.If a thickening agent is present in the formulation, the thickening agent increasesthe viscosity of the formulation following administration. Preferably theformulation contains an insulin, a diluent, glucose oxidase and peroxidase.Following administration to a patient, the insulin is released from the formulationsas a function of the patient's tissue glucose level, which in turn maintainsthe patient's blood glucose level within an optimum range. The formulationis often referred to as a "smart" formulation since it modifies itsrelease rate of insulin according to the patient's needs at a particulartime. In a preferred embodiment, the formulation is designed to release insulininto the systemic circulation over time with a basal release profile followinginjection in a patient. In another embodiment, the formulation is designed torelease insulin into the systemic circulation over time with a non-basal releaseprofile following injection in a patient, such as a regular human insulin releaseprofile or a prandial release profile.
